Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis

Bone Marrow Transplant. 2015 Nov;50(11):1424-31. doi: 10.1038/bmt.2015.172. Epub 2015 Aug 3.

Abstract

In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower transplant-related mortality rates compared with myeloablative conditioning. However, lowering the intensity of conditioning may increase the risk of graft failure in myelofibrosis, although hitherto this has not been indisputably proven. We here report the outcome of 53 patients who underwent allogeneic SCT with different conditioning regimens (RIC and non-myeloablative (NMA)) in three transplantation centers in the Netherlands. The cumulative incidence of graft failure within 60 days after SCT was high (28%), and this was primarily associated with the intensity of the conditioning regimen. Cumulative neutrophil engraftment at 60 days was lower in patients who received NMA conditioning compared with those who received RIC (56% vs 84%, P=0.03). Furthermore, of six patients who received a second transplantation after graft failure, the three patients with RIC regimens subsequently engrafted, whereas the three patients who received a second NMA regimen did not. This study indicates that in myelofibrosis, NMA regimens result in high engraftment failure rates. We propose the use of more intensive conditioning regimens, incorporating busulfan or melphalan.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Busulfan / therapeutic use
  • Calreticulin / genetics
  • Combined Modality Therapy
  • Cord Blood Stem Cell Transplantation*
  • Cyclophosphamide / therapeutic use
  • Disease Progression
  • Female
  • Graft Survival*
  • Humans
  • Janus Kinase 2 / genetics
  • Male
  • Melphalan / therapeutic use
  • Middle Aged
  • Myeloablative Agonists / therapeutic use*
  • Neutrophils / transplantation
  • Peripheral Blood Stem Cell Transplantation*
  • Polycythemia Vera / complications
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / etiology
  • Primary Myelofibrosis / genetics
  • Primary Myelofibrosis / therapy*
  • Receptors, Thrombopoietin / genetics
  • Retrospective Studies
  • Thrombocythemia, Essential / complications
  • Transplantation Conditioning / methods*
  • Treatment Outcome
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use
  • Whole-Body Irradiation
  • Young Adult

Substances

  • CALR protein, human
  • Calreticulin
  • Myeloablative Agonists
  • Receptors, Thrombopoietin
  • MPL protein, human
  • Cyclophosphamide
  • JAK2 protein, human
  • Janus Kinase 2
  • Vidarabine
  • Busulfan
  • fludarabine
  • Melphalan